A polymorphic enhancer near GREM1 influences bowel cancer risk through differential CDX2 and TCF7L2 binding. (Cell reports, 2014)

(untitled) - Lewis, A; Freeman-Mills, L; de la Calle-Mustienes, E; Giráldez-Pérez, R; Davis, H; Jaeger, E; Becker, M; Hubner, N; Nguyen, L; Zeron-Medina, J; Bond, G; Stunnenberg, H; et al.